Oxford Biomedica (LON:OXB) Releases Earnings Results

Oxford Biomedica (LON:OXB) released its earnings results on Wednesday. The biopharmaceutical company reported GBX (30.39) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Oxford Biomedica had a negative net margin of 23.23% and a negative return on equity of 54.51%.

Oxford Biomedica Stock Performance

Shares of OXB stock opened at GBX 483 on Thursday. The stock has a market capitalization of £584.66 million, a P/E ratio of -17.94 and a beta of 1.09. The company has a current ratio of 2.21, a quick ratio of 1.67 and a debt-to-equity ratio of 273.08. The firm’s 50 day moving average is GBX 512.48 and its 200 day moving average is GBX 576.03. Oxford Biomedica has a 12 month low of GBX 420 and a 12 month high of GBX 952.

Key Headlines Impacting Oxford Biomedica

Here are the key news stories impacting Oxford Biomedica this week:

• Positive Sentiment: Client wins accelerated. Oxford Biomedica reported 17 new clients during the period, described as record commercial wins. The expanding customer base supports future manufacturing and development revenue. OXB wins 17 new clients as its expansion gathers pace
• Positive Sentiment: Revenue growth and guidance were maintained. First-half revenue reached £80.2 million, representing approximately 9% growth, while management maintained its full-year 2026 outlook. The client pipeline is also expected to improve revenue visibility. Oxford Biomedica H1 Revenue Reaches £80.2 Million as FY2026 Guidance Maintained
• Positive Sentiment: Technology partnership expands operational capabilities. Oxford Biomedica is deploying Veeva Quality Cloud as part of a global quality transformation. The move may improve quality-system efficiency and support the company’s growing international operations. Oxford Biomedica Advances Global Quality Transformation with Veeva Quality Cloud
• Neutral Sentiment: Veeva selected another major biopharmaceutical customer for Vault CRM. The announcement reinforces Veeva’s market position, but its direct impact on Oxford Biomedica is limited beyond the broader relationship between the companies. Veeva Systems Vault CRM Extends Market Leadership
• Negative Sentiment: Profitability remains the main concern. Oxford Biomedica reported a quarterly loss of GBX 30.39 per share, while its first-half loss widened. The company also reported a negative net margin and negative return on equity, leaving investors focused on the timing of a return to profitability. Oxford Biomedica earnings results

Wall Street Analyst Weigh In

OXB has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 595 price objective on shares of Oxford Biomedica in a research note on Wednesday, September 2nd. Jefferies Financial Group restated a “buy” rating and issued a GBX 8.27 target price on shares of Oxford Biomedica in a research note on Tuesday, June 2nd. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a GBX 900 price target on shares of Oxford Biomedica in a research note on Tuesday, September 1st. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of GBX 580.85.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.